Also for TROPION 01, obviously need OS. For field as a whole we could use structured crossover trials from ADC1–>ADC2. And we need a better understanding of resistance: resistance based on target vs payload.

TROPION Breast01 updated from October ESMO shows 2.4 mo improvement in PFS vs ineffective late line CT with improved QOL vs CT. Question: should we require, going forward, comparisons vs other ADCs rather than vs essentially inactive CT?

Monarch 3 frontline OS results for Abema continue to show numerically impressive improvements but a significant p value remains frustratingly elusive. This is confusing given positive second line and adjuvant results.

With both neoadjuvant Nivo and Pembro in ER pos BC pCR rates increase strongly as PD-L1 increases. Two questions: should we use PD-L1 as a predictive biomarker, and should we use either of these drugs in the absence of solid EFS improvements?

A press release on our recent study: med.stanford.edu/news/all-news/…

Excited to see our paper on antibiotics and triple-negative breast cancer mortality just published in Nature Communications: rdcu.be/c9Nkz.

A book plug for my friend and colleague Chadi Nabhan. His Toxic Exposure tells the fascinating story of the linkage on Monsanto’s Roundup herbicide and lymphoma, told through the lens of the trials that ensued. Suspenseful and scientific.

If you’re looking 4 a book 2 read/listen, consider #ToxicExposure ⁦Hopkins Press⁩ describing the first 3 Monsanto trials.

Available everywhere: link: a.co/d/2jnROSu

Taped this video in SF 2 weeks ago in the courthouse where 1st trial took place.

Check the book out.

Excellent work by the Caris Life Sciences POA GI group w this recent The Lancet Oncology paper just out using the dataset & collab effort. Congrats to all authors. Emil Lou, MD, PhD, FACP Benjamin Weinberg, MD, FACP John Marshall Moh’d khushman Matthew Oberley Joanne Xiu and many others. 👏👏👏

thelancet.com/journals/lanon…

This is a great start! Let’s not forget people living with metastatic cancers along the way.

#bcsm Project Life

How common is ER-loss in invasive lobular #carcinoma ? In a real-world dataset, Dr. Whitney Hensing and colleagues found it occurs in around 1 in 10 cases. Check out Dr. Hensing’s poster to discover more and learn how ER-loss impacts prognosis. #SABCS22

🤩🤩🤩
Come stop by our poster outside of Hall 3 at #SABCS22 & listen in to the HER2-low special session! Excited to be able to share our research SABCS with my mentor Stephanie Graff, MD, FACP, FASCO and collab with Caris Life Sciences Legorreta Cancer Center at Brown University Duke Cancer

Did you know that clock genes are novel predictive and prognostic biomarkers for #breastcancer ? Visit Dr. Priya Jayachandran’s poster at #SABCS22 to discover the association between clock gene expression and breast cancer subtype and survival.

Dr. Whitney Hensing presented findings on the prevalence and prognosis of ER-Loss in advanced invasive lobular carcinoma during #SABCS22 .

#precisionmedicine
#breastcancerresearch

Congratulations to BCRF investigator Dr. Norman Wolmark, who receives the Brinker Award for Scientific Distinction in Clinical Research today at #SABCS22 for his contributions to patient care—most notably pioneering lumpectomy. SABCS

Today Dr. Priya Jayachandran presented details on altered expression of clock genes associated with breast cancer subtype and survival. #SABCS22

#precisiononcology
#breastcancerresearch

#VailWorkshop reunion at #SABCS2022 —great fun catching up friends/colleagues (missing a few in the 📸!) AACR ASCO SABCS

Monarch-2 Final OS George W Sledge MD
🔹45.8 Abema/FULV vs 37.2 FULV alone month OS, HR=0.78
#SABCS22 OncoAlert

The 🐐 George W Sledge MD who continues to be a true innovator in the the field of #BreastCancer #PrecisionMedicine SABCS Glad he’s on our team now Caris Life Sciences 🎯 🧬 #WinTheDay #SABCS22